The 10-year cumulative incidence of CIN3+ among the HPV mRNA-positive women was 20.8% (CI: 16.2–25.4), whilst 1.1% in HPV mRNA negative women at baseline.
The low long-term risk of CIN3+ among HPV mRNA-negative women, and the high long-term risk among HPV mRNA-positive women strengthens the evidence that the
five-type HPV mRNA test is an appropriate screening test for women of all ages.
You can read the full text here: https://www.mdpi.com/2072-6694/15/12/3106
Figure 1. Cumulative incidence of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) (%) by human papillomavirus (HPV) type from baseline throughout 120 months of follow-up.